Business
Anixa Biosciences Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
SAN JOSE, Calif., July 20, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"SAN JOSE, Calif., July 20, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that due to public health and safety concerns related to the ongoing COVID-19 global pandemic and to support the health and well-being of its stockholders, employees and others, the Company is changing its 2020 Annual Meeting of Stockholders (the \"Annual Meeting\") to a virtual-only format that will be held via live audio webcast. \n\n \n \n \n \n \n \n\n \nAs previously announced, the Annual Meeting will be held on August 13, 2020 at 10:00 a.m. Pacific Time, but will be held via live audio webcast. Any shareholders that wish to participate, vote and ask questions at the virtual Annual Meeting should log in at www.virtualshareholdermeeting.com/ANIX2020 and then enter the control number found on their proxy card, voting instruction or notice previously received. Further information regarding this change to a virtual Annual Meeting can be found in the supplemental proxy materials filed by Anixa with the Securities and Exchange Commission on July 20, 2020.\nAbout Anixa Biosciences, Inc.Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutic portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company's vaccine portfolio consists of a technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC). Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.\nForward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words \"believes,\" \"expects,\" \"intends,\" \"plans,\" \"anticipates,\" \"likely,\" \"will\...